Who next in antibiotic M&A gold rush?
This article was originally published in Scrip
Executive Summary
Shares in companies engaged in antibiotic development basked in the reflected glow of Merck & Co's just announced $9.5bn takeout deal for Cubist Pharmaceuticals (scripintelligence.com, 9 December 2014). This acquisition follows hot on the heels of Actavis's $675-820m purchase agreement for fellow antibiotics player Durata Therapeutics (scripintelligence.com, 7 October 2014), and is only the most ostentatious example of a deal-making trend that has been gathering pace over the past year or so.
You may also be interested in...
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.